Our Pipeline

Enabled by our proprietary drug discovery platform, we have developed a diverse pipeline of wholly-owned drug candidates.⁽¹⁾

Pipeline graphic is not for promotional use.

Research IND-Enabling Phase 1 Phase 1/2 Phase 3 Regulatory

Updated as of January 2023; (1) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (2) Without an exon 9, 13, or 14 mutation; (3) Agreement with Sprint Bioscience for exclusive in-license worldwide rights to a research-stage program targeting VPS34.